Discovering Residual Pathways Driving Asthma Exacerbations in the Era of Biologic Therapy

Weston T Powell^{1

2}, Jason S Debley^{1

2}

Affiliations

¹ Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington.
² Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle.

Weston T Powell et al. JAMA. 2025.

. 2025 Aug 12;334(6):493-495.

doi: 10.1001/jama.2025.11227.

Weston T Powell^{1

2}, Jason S Debley^{1

2}

¹ Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington.
² Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle.

No abstract available

Comment in

Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial.
Altman MC, Janczyk T, Murphy RC, Jayavelu ND, Calatroni A, Kattan M, Gill MA, Stokes J, Liu AH, Khurana Hershey GK, Sherenian M, Kumar R, Robison RG, Gruchalla RS, O'Connor GT, Zoratti EM, Teach SJ, Lynch SV, Dill-McFarland KA, Becker PM, Togias A, Gern JE, Bacharier LB, Busse WW, Jackson DJ; Inner City Asthma Consortium and Childhood Asthma in Urban Settings Network. Altman MC, et al. JAMA Pediatr. 2025 Sep 1;179(9):957-970. doi: 10.1001/jamapediatrics.2025.2044. JAMA Pediatr. 2025. PMID: 40658400 Clinical Trial.